Your browser doesn't support javascript.
loading
BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Patel, Shital; Nayernama, Afrouz; Jones, Steven Christopher; de Claro, Romeo Angelo; Waldron, Peter E.
Affiliation
  • Patel S; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Nayernama A; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Jones SC; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • de Claro RA; Division of Hematologic Malignancies I, Office of Oncologic Diseases, U.S. Food and Drug Administration, Silver Spring, Maryland.
  • Waldron PE; Division of Pharmacovigilance, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland.
Am J Hematol ; 95(12): E332-E335, 2020 12.
Article in En | MEDLINE | ID: mdl-32918288

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Protein Kinase Inhibitors / Hyperthyroidism / Hypothyroidism Type of study: Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Protein Kinase Inhibitors / Hyperthyroidism / Hypothyroidism Type of study: Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2020 Type: Article